Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)
- 21:00 - 23:59
- 8/06/2022
- Location: On-Demand
- Not for CME Credit
- Type: Workshop
- Track: N/A
- Moderators:Yi-Long Wu, Chunxue Bai, Caicun Zhou, Karen Kelly
-
+
WS08.07 - How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC
21:50 - 22:10 | Presenter: Jie Hu
- Abstract
Loading...
-
+
MA02 - Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics
- 10:45 - 11:45
- 8/07/2022
- Location: Hall C8
- Not for CME Credit
- Type: Mini Oral
- Track: Tumor Biology and Biomarkers
- Moderators:Erik Thunnissen, Rafael Rosell
-
+
MA02.05 - Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
10:57 - 11:02 | Presenter: Jie Huang
- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-056 - Pemetrexed-Based Chemotherapy Plus ICIs or Bevacizumab as First-Line Strategy for Patients with Lung Adenocarcinoma in Real-World Setting
Presenter: Xin Li- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-068 - ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)
Presenter: Jie Huang- Abstract
Loading... -
+
EP08.02-136 - Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer
Presenter: Juan Shen- Abstract
Loading...
